10-Q: AnaptysBio Q3 2026: Revenue Dip, Litigation Looms

AnaptysBio reports a decrease in collaboration revenue for Q3 2026, alongside ongoing litigation with GSK and a stable financial position.

Summary

• AnaptysBio reported collaboration revenue of $30.3 million for the three months ended September 30, 2026, a decrease from $76.3 million in the same period of 2025.
• Operating expenses were $10.4 million, a significant decrease from $41.6 million in Q3 2025, largely due to the spin-off of its Biopharma segment.
• Net income for the period was $3.9 million, compared to $15.1 million in Q3 2025.
• The company had $153.0 million in cash, cash equivalents, and investments as of September 30, 2026, and believes it has sufficient funds for at least the next twelve months.
• The company is involved in ongoing litigation with GSK regarding their collaboration agreement.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with stable financial performance and ongoing development, but with significant litigation risks and a notable decrease in collaboration revenue.

Positives

• The company maintains a strong cash position of $153.0 million, providing ample runway for at least the next twelve months.
• Operating expenses have significantly decreased to $10.4 million due to the recent spin-off of the Biopharma segment.
• The Vanda collaboration shows progress with a BLA submission for Quimilza accepted by the FDA in February 2026, with a target action date of December 12, 2026.
• Jemperli continues to receive regulatory approvals and expanded indications, including a recent FDA accelerated approval in October 2026 for locally advanced rectal cancer.

Negatives

• Collaboration revenue decreased significantly to $30.3 million in Q3 2026 from $76.3 million in Q3 2025, primarily due to a $50 million decrease in GSK milestone revenue.
• The company is involved in ongoing litigation with GSK, which has led to increased legal expenses ($4.8 million in Q3 2026).
• Non-cash interest expense related to the sale of future royalties remains substantial at $18.7 million for the quarter.
• The company's reliance on GSK for Jemperli revenue presents a significant risk if GSK's commercialization efforts falter.

Risks

• The company's financial results are heavily dependent on GSK's ability to successfully develop and commercialize Jemperli.
• Ongoing litigation with GSK could have a material negative impact on the company's rights under the agreement and its financial position.
• Competition from other oncology therapies, such as Keytruda, could reduce Jemperli sales and, consequently, the royalties payable to AnaptysBio.
• The company faces risks related to intellectual property protection, including potential challenges to patents and the ability to maintain exclusivity.
• The market price of AnaptysBio's stock has been and may continue to be volatile.
• The spin-off of First Tracks Biotherapeutics may lead to operational disruptions and requires management to balance attention between two companies.

Future Outlook

The company expects to continue managing its financial collaborations with GSK and Vanda, focusing on protecting and returning value from its royalties. Management believes current resources will fund operating plans for at least the next 12 months. Future collaboration revenue is expected to fluctuate based on milestone payments and sales under existing agreements.

Management Comments

• AnaptysBio manages the financial collaborations for Jemperli with GSK and Quimilza with Vanda, with a focus on protecting and returning the value of its royalties to shareholders.
• We do not expect to continue to incur net operating losses for at least the next several years as we hold and continue to manage the financial collaboration for Jemperli with GSK and for Quimilza with Vanda, with a focus on protecting and returning value of the royalties to its stockholders.

Industry Context

StockSavvy.ai notes that AnaptysBio's focus on royalty management in the post-spin-off environment aligns with a trend of specialized biotech companies optimizing value from existing assets. However, the significant decrease in collaboration revenue highlights the inherent volatility and dependence on partner success in this model.

Comparison to Industry Standards

• The decrease in collaboration revenue from $76.3 million to $30.3 million year-over-year is a significant decline, which is concerning for a company focused on royalty streams. Industry peers often aim for more stable or growing revenue from their key collaborations.
• The substantial non-cash interest expense of $18.7 million related to royalty monetization agreements is a common, but impactful, financial instrument in the biotech sector. Companies like Royalty Pharma or other royalty-focused funds operate in this space, but AnaptysBio's high effective interest rate (31.1%) on the Jemperli agreement is notable.
• The increase in General and Administrative expenses, particularly legal fees related to the GSK litigation, is a significant concern. While litigation is not uncommon, a $4.8 million expense in a single quarter for this purpose can be a drag on profitability and distract management.

Legal Proceedings

• AnaptysBio filed a lawsuit against TESARO, Inc. (Tesaro) and GSK alleging material breach of the Collaboration and Exclusive License Agreement. Tesaro and GSK also filed suit against AnaptysBio. The trial on remaining claims concluded, with post-trial briefing and arguments completed. AnaptysBio is seeking the return of dostarlimab rights.

Related Party Transactions

• Sublease agreement with First Tracks Biotherapeutics, a former segment of AnaptysBio, for approximately 45,000 square feet of space.

Stakeholder Impact

• Shareholders may be impacted by the decrease in collaboration revenue and the ongoing litigation, potentially affecting stock price.
• The company's ability to fund future operations relies on its existing cash reserves and future royalty payments, impacting creditors and suppliers.
• The spin-off of the Biopharma segment may affect employees who transitioned to First Tracks Biotherapeutics.

Next Steps

• Continue to manage financial collaborations with GSK and Vanda.
• Monitor the progress of Vanda's BLA submission for Quimilza, with an FDA target action date of December 12, 2026.
• Await the outcome of the ongoing litigation with GSK.
• Continue to protect and return value from existing royalty streams.

Key Dates

Recommendation

AnaptysBio presents a mixed picture. While the company maintains a strong cash position and has promising developments with Quimilza and continued Jemperli approvals, the significant drop in collaboration revenue and the ongoing, costly litigation with GSK introduce substantial risk. The company's future hinges heavily on the success of its partners and the resolution of legal disputes. Therefore, a 'hold' recommendation is appropriate, pending further clarity on these critical factors.

Keywords

AnaptysBio, Jemperli, GSK, collaboration revenue, royalty monetization, Vanda Pharmaceuticals, Quimilza, litigation